BGI
FTH

B Group Inc’s Faeth Therapeutics FTH Stock Holding History

B Group Inc’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
+610,169
New +$14.1M 7.16% 5

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

B Group Inc's FTH Position: Q2 2026 in Review

B Group Inc opened a new position in Faeth Therapeutics (FTH) in Q2 2026: 610,169 shares worth $15.3M. The stake represents 7.16% of the portfolio and ranks #5 among its holdings.

45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • B Group Inc held 610,169 shares of Faeth Therapeutics worth $15.3M as of Q2 2026.
  • Faeth Therapeutics was a new B Group Inc position in Q2 2026.
  • Faeth Therapeutics made up 7.16% of B Group Inc's portfolio in Q2 2026, its #5 holding.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.